Logo image of PHGE

BIOMX INC (PHGE) Stock Fundamental Analysis

USA - NYSEARCA:PHGE - US09090D3017 - Common Stock

0.403 USD
+0.01 (+3.33%)
Last: 11/7/2025, 8:08:10 PM
0.408 USD
+0 (+1.24%)
After Hours: 11/7/2025, 8:08:10 PM
Fundamental Rating

2

Taking everything into account, PHGE scores 2 out of 10 in our fundamental rating. PHGE was compared to 531 industry peers in the Biotechnology industry. The financial health of PHGE is average, but there are quite some concerns on its profitability. PHGE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PHGE has reported negative net income.
In the past year PHGE has reported a negative cash flow from operations.
PHGE had negative earnings in each of the past 5 years.
PHGE had a negative operating cash flow in each of the past 5 years.
PHGE Yearly Net Income VS EBIT VS OCF VS FCFPHGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of PHGE (-48.80%) is comparable to the rest of the industry.
PHGE has a Return On Equity (-96.91%) which is in line with its industry peers.
Industry RankSector Rank
ROA -48.8%
ROE -96.91%
ROIC N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
PHGE Yearly ROA, ROE, ROICPHGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PHGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHGE Yearly Profit, Operating, Gross MarginsPHGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

PHGE has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PHGE has been increased compared to 5 years ago.
PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PHGE Yearly Shares OutstandingPHGE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHGE Yearly Total Debt VS Total AssetsPHGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -9.53, we must say that PHGE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PHGE (-9.53) is worse than 71.64% of its industry peers.
There is no outstanding debt for PHGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.53
ROIC/WACCN/A
WACCN/A
PHGE Yearly LT Debt VS Equity VS FCFPHGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

PHGE has a Current Ratio of 2.66. This indicates that PHGE is financially healthy and has no problem in meeting its short term obligations.
PHGE has a Current ratio of 2.66. This is in the lower half of the industry: PHGE underperforms 68.10% of its industry peers.
A Quick Ratio of 2.66 indicates that PHGE has no problem at all paying its short term obligations.
PHGE has a worse Quick ratio (2.66) than 66.23% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
PHGE Yearly Current Assets VS Current LiabilitesPHGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PHGE have decreased strongly by -60.04% in the last year.
EPS 1Y (TTM)-60.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.74% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.25%
EPS Next 2Y23.86%
EPS Next 3Y14.15%
EPS Next 5Y6.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHGE Yearly Revenue VS EstimatesPHGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 100M 200M 300M
PHGE Yearly EPS VS EstimatesPHGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PHGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHGE Price Earnings VS Forward Price EarningsPHGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHGE Per share dataPHGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as PHGE's earnings are expected to grow with 14.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.86%
EPS Next 3Y14.15%

More info and screens

0

5. Dividend

5.1 Amount

PHGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMX INC

NYSEARCA:PHGE (11/7/2025, 8:08:10 PM)

After market: 0.408 +0 (+1.24%)

0.403

+0.01 (+3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners40.03%
Inst Owner Change-0.73%
Ins Owners1.46%
Ins Owner Change0%
Market Cap10.70M
Revenue(TTM)N/A
Net Income(TTM)-18.57M
Analysts82.5
Price Target15.81 (3823.08%)
Short Float %0.81%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.96%
Min EPS beat(2)-0.76%
Max EPS beat(2)42.68%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.95%
EPS NY rev (1m)0%
EPS NY rev (3m)5.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 1.5
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0
BVpS0.72
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.8%
ROE -96.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -9.53
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.92%
Cap/Depr(5y)40.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.86%
EPS Next Y43.25%
EPS Next 2Y23.86%
EPS Next 3Y14.15%
EPS Next 5Y6.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.68%
EBIT Next 3Y-11.29%
EBIT Next 5Y-5.98%
FCF growth 1Y-34.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.22%
OCF growth 3YN/A
OCF growth 5YN/A

BIOMX INC / PHGE FAQ

What is the fundamental rating for PHGE stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHGE.


What is the valuation status for PHGE stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOMX INC (PHGE). This can be considered as Overvalued.


Can you provide the profitability details for BIOMX INC?

BIOMX INC (PHGE) has a profitability rating of 1 / 10.


Can you provide the financial health for PHGE stock?

The financial health rating of BIOMX INC (PHGE) is 6 / 10.


What is the expected EPS growth for BIOMX INC (PHGE) stock?

The Earnings per Share (EPS) of BIOMX INC (PHGE) is expected to grow by 43.25% in the next year.